The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
David I. Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Pfizer; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Expert Testimony - Medivation; Teva
Daniel Peter Petrylak
Consultant or Advisory Role - Astellas Pharma; Dendreon
Research Funding - Astellas Pharma; Dendreon
Christopher Michael Pieczonka
Consultant or Advisory Role - Dendreon
Honoraria - Astellas Pharma; Dendreon
Research Funding - Astellas Pharma; Dendreon
Andrew Sandler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Charles G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Janssen